Baseline monocyte SGLT2 mRNA expression and changes in the fibrosis-4 index after luseogliflozin treatment in participants with type 2 diabetes and MASLD
Diabetology International · 2027-01 · 18 (1)
DOI: 10.1007/s13340-026-00941-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetology International, online erschienen am 31.10.2026. Verfasst von Hideyuki Okuma. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Nerima Hikarigaoka Hospital, Nerima-Ku, 179-0072 Japan. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in type 2 diabetes. We investigated the association between monocyte mRNA expression of sodium-glucose cotransporter 2 (SGLT2), the molecular target of luseogliflozin, and changes in the fibrosis-4 (FIB-4) index during treatment with this agent.
Methods
This single-center retrospective observational study used prospectively collected peripheral blood monocyte samples from 82 participants with type 2 diabetes and MASLD who had received luseogliflozin for at least 6 months. Baseline monocyte SGLT2 mRNA expression was measured using quantitative real-time polymerase chain reaction. Clinical and laboratory parameters, including FIB-4 index, were evaluated at baseline and 6 months after luseogliflozin initiation. Changes were calculated as the 6-month value minus the baseline value; therefore, negative values indicated reductions.
Results
After 6 months, waist circumference, hemoglobin A1c, liver enzyme levels, high-sensitivity C-reactive protein, and the FIB-4 index decreased significantly. Baseline monocyte SGLT2 mRNA expression was negatively correlated with the change in the FIB-4 index, indicating that higher baseline expression was associated with a greater reduction. In multiple regression analyses, natural-log-transformed baseline monocyte SGLT2 mRNA expression remained associated with the change in the FIB-4 index after adjustment for baseline clinical variables.
Conclusions
Higher baseline monocyte SGLT2 mRNA expression was associated with a greater reduction in the FIB-4 index after luseogliflozin treatment. This finding should be interpreted as an exploratory association between a cell-specific transcriptomic feature and changes in a fibrosis-related index, rather than as evidence of functional SGLT2 signaling in monocytes or histological fibrosis regression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Diabetes and Endocrinology, Nerima Hikarigaoka Hospital, Nerima-Ku, 179-0072 Japan.
ORCID-Profile: Hideyuki Okuma
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Okuma, H. (2027). Baseline monocyte SGLT2 mRNA expression and changes in the fibrosis-4 index after luseogliflozin treatment in participants with type 2 diabetes and MASLD. Diabetology International, 18(1). https://doi.org/10.1007/s13340-026-00941-2
Vancouver
Okuma H. Baseline monocyte SGLT2 mRNA expression and changes in the fibrosis-4 index after luseogliflozin treatment in participants with type 2 diabetes and MASLD. Diabetology International. 2027;18(1). doi:10.1007/s13340-026-00941-2
BibTeX
@article{Okuma2027,
author = {Okuma, Hideyuki},
title = {Baseline monocyte SGLT2 mRNA expression and changes in the fibrosis-4 index after luseogliflozin treatment in participants with type 2 diabetes and MASLD},
journal = {Diabetology International},
year = {2027},
volume = {18},
number = {1},
doi = {10.1007/s13340-026-00941-2}
}
EUVIMED